Topics

Eisai, Biogen To Discontinue Elenbecestat Phase III Studies

08:31 EDT 13 Sep 2019 | FinanzNachrichten

WESTON (dpa-AFX) - Eisai Co. Ltd., a global research and development-based pharmaceutical company headquartered in Japan, and Biogen Inc. (BIIB) have decided to discontinue the Phase III clinical ...

Original Article: Eisai, Biogen To Discontinue Elenbecestat Phase III Studies

NEXT ARTICLE

More From BioPortfolio on "Eisai, Biogen To Discontinue Elenbecestat Phase III Studies"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...